Chemotherapy and radiation are common treatments for lung cancer. However, immunotherapy may be able to help double a patient's survival, according to a new report. Researchers from New York ...

Squamous cell carcinoma of the lung is linked to smoking and requires early detection and accurate staging for effective treatment. Diagnosis involves imaging and biopsy, with the TNM system used to ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether ...

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...

Combining osimertinib with chemotherapy significantly improved overall survival in advanced EGFR-mutated non-small cell lung cancer. The FLAURA2 trial showed a consistent survival benefit and extended ...

Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 trial.

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...